Lasa Supergenerics Limited has announced the resignation of its Whole-time Director Mr. Prathmesh Chalke, effective December 31, 2025. The pharmaceutical company informed both BSE and NSE about this key management change in compliance with regulatory requirements.

Director Resignation Details

The company filed the resignation intimation under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The resignation becomes effective from the closing hours of Wednesday, December 31, 2025.

Resignation Communication

In his resignation letter dated December 11, 2025, Mr. Chalke expressed his intention to step down from his directorial position. He confirmed that there are no material reasons for his resignation beyond those provided in his resignation communication to the company.

The departing director stated his gratitude for the opportunities, growth, and experience gained during his tenure with the company. He has committed to ensuring a smooth handover process and completing any pending tasks before his departure.

Regulatory Compliance

The company has fulfilled its disclosure obligations by informing both stock exchanges where its shares are listed:

• BSE Limited (Code: 540702)
• National Stock Exchange (Code: LASA)

The resignation details and supporting documentation have been made available on the company's website at www.lasalabs.com as part of transparency requirements.

Company Leadership

The resignation intimation was signed by Mr. Omkar Pravin Herlekar (DIN: 01587154), who serves as Chairman and Managing Director of Lasa Supergenerics Limited. The company is headquartered at C-4, C-4/1, M.I.D.C. Lote Parshuram Industrial Area, Tal-Khed, Dist-Ratnagiri 415722.

Lasa Supergenerics Limited, a pharmaceutical company based in Maharashtra, has reported a significant net loss of Rs 2,821.93 crore for the quarter ended September 30. This substantial loss is primarily attributed to a catastrophic fire incident that occurred at the company's main manufacturing facility in May.

Fire Incident and Its Impact

The fire, which broke out on May 18 at the company's factory located in the Lote Parshuram Industrial area of Ratnagiri, Maharashtra, resulted in extensive damage to the facility. The incident led to the destruction of inventories and equipment valued at Rs 1,973.62 crore. This unit, referred to as the 'Mother Unit', was central to the company's primary production activities.

Operational Halt and Financial Implications

As a consequence of the fire, Lasa Supergenerics has suspended all manufacturing operations across its facilities. The company's other owned and leased units, which were dependent on the output from the affected C-4 unit for further processing and production, have also ceased activities. This operational shutdown has significantly impacted the company's financial performance for the quarter.

Financial Overview

The financial impact of the fire incident is reflected in the company's quarterly results:

It's important to note that the affected assets were not covered by insurance, exacerbating the financial impact on the company.

Management's Response and Future Plans

In light of these challenges, the management of Lasa Supergenerics has expressed its inability to immediately recommence manufacturing activities at its facilities. This is due to a range of issues, including pending statutory clearances and operational constraints.

However, the company is actively exploring alternative options to resume business operations. These include:

1. Entering into contract manufacturing arrangements
2. Leasing facility options

Both of these strategies are subject to obtaining necessary regulatory approvals and consents.

Regulatory Compliance

The company has duly informed the stock exchanges, Factory Inspector, and the Office of the Labour Commissioner regarding the suspension of operations, in compliance with regulatory requirements.

Going Concern and Auditor's Review

The company's auditors, Gupta Rustagi & Co., have conducted a limited review of the financial results. They have highlighted the fire incident and its impact as exceptional items in their review report. The auditors also noted the management's efforts to explore alternative business continuity options.

Conclusion

The fire incident at Lasa Supergenerics' main manufacturing facility has had a severe impact on the company's operations and financial performance. As the company navigates through this challenging period, stakeholders will be closely watching its efforts to recover and resume operations through alternative arrangements. The coming quarters will be crucial in determining the company's ability to overcome this setback and return to normal operations.